<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00152477</url>
  </required_header>
  <id_info>
    <org_study_id>C79102</org_study_id>
    <secondary_id>EudraCT 2005-001731-30</secondary_id>
    <nct_id>NCT00152477</nct_id>
  </id_info>
  <brief_title>A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer</brief_title>
  <official_title>A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjects With Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <brief_summary>
    <textblock>
      A 2-part study to examine safety, tolerability and pharmacokinetics (part 1), and anti-tumour
      effects (part 2), of CDP791 combined with carboplatin and paclitaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two part study to investigate the safety and anti-tumour effects of standard
      chemotherapy, plus an investigational drug (CDP791), in patients with advanced non small cell
      lung cancer.

      In part one, patients receive carboplatin and paclitaxel chemotherapy together with one of 2
      doses of CDP791. The main aim of this part is to investigate safety and tolerability of
      carboplatin/paclitaxel plus CDP791.

      If part one confirms that the combination of drugs is safe and well tolerated, 156 patients
      will enter part 2. They will be randomized to receive either carboplatin/paclitaxel (C/P)
      alone, or C/P plus one of 2 doses of CDP791. The main aim of this part of the study is to
      compare the anti-tumor effects of CDP791 plus C/T with those of C/T alone. Participants will
      receive up to six cycles of chemotherapy with or without CDP791. Those whose disease
      stabilizes, or responds, will be eligible to continue to receive CDP791. Participants in the
      C/T alone arm whose disease progresses will be eligible to receive CDP791 monotherapy.

      Participants will be followed up longterm, so that survival can be measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumour response rate at 18 weeks.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>analyzed alongside other parameters</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>at specified % event rates</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>analyzed alongside other parameters</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at specified % event rates</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>analyzed alongside other parameters</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>analyzed alongside other parameters</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Carcinoma</condition>
  <condition>Non-Squamous Non-Small-Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Carboplatin/Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin and paclitaxel alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin/Paclitaxel/CDP791 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin and paclitaxel plus CDP791 10mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin/Paclitaxel/CDP791 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin and paclitaxel plus CDP791 20mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.
Each cycle to be repeated every three weeks for a maximum of six cycles.</description>
    <arm_group_label>Carboplatin/Paclitaxel</arm_group_label>
    <arm_group_label>Carboplatin/Paclitaxel/CDP791 10mg</arm_group_label>
    <arm_group_label>Carboplatin/Paclitaxel/CDP791 20mg</arm_group_label>
    <other_name>CBDCA, Paraplatin, JM-8, NSC 241240</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.</description>
    <arm_group_label>Carboplatin/Paclitaxel</arm_group_label>
    <arm_group_label>Carboplatin/Paclitaxel/CDP791 10mg</arm_group_label>
    <arm_group_label>Carboplatin/Paclitaxel/CDP791 20mg</arm_group_label>
    <other_name>Taxol, NSC #673089</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDP791 10mg/kg</intervention_name>
    <description>CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.</description>
    <arm_group_label>Carboplatin/Paclitaxel/CDP791 10mg</arm_group_label>
    <arm_group_label>Carboplatin/Paclitaxel/CDP791 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDP791 20mg/kg</intervention_name>
    <description>CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.</description>
    <arm_group_label>Carboplatin/Paclitaxel/CDP791 10mg</arm_group_label>
    <arm_group_label>Carboplatin/Paclitaxel/CDP791 20mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with Stage IIIb (with malignant pleural effusion or if no
             pleural effusion is present subjects who are not candidates for combined modality
             therapy), Stage IV, or recurrent non-squamous, non-small-cell lung carcinoma.

          -  The subject must be aged 18 years or above.

          -  The subject must have ECOG performance status of 0 or 1 and a life expectancy of at
             least three months.

          -  Subjects will have measurable disease.

          -  The subject must be able to understand the information provided to them and to give
             written informed consent.

          -  Female subjects must be either postmenopausal, surgically sterilized, or using a
             method of contraception judged reliable by the Investigator.

          -  Male subjects must be using a method of contraception judged reliable by the
             Investigator.

        Exclusion Criteria:

          -  Subjects with squamous cell lung carcinoma.

          -  Subjects with lung lesions located centrally in the chest that involve major blood
             vessels.

          -  Concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ
             of the cervix. Subjects with previous malignancies are eligible provided that they
             have been disease free for five years or more.

          -  Presence of additional major chronic disease such as hepatic or renal dysfunction,
             cardiac dysfunction, peripheral vascular disease, evidence of a myocardial infarction
             within six months of Screening visit, tuberculosis or epilepsy.

          -  Subjects known to be infected with hepatitis B or C virus or HIV 1 or 2.

          -  Any evidence of serious active infection (ie requiring an iv antibiotic or antiviral
             agent).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matrahaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Otwock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Radom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moskow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small-cell-lung cancer</keyword>
  <keyword>carboplatin</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>VEGF</keyword>
  <keyword>monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 8, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

